LN 144

Drug Profile

LN 144

Alternative Names: Autologous T-cell therapy - Iovance Biotherapeutics; Contego; LN144; TILs - Iovance Biotherapeutics; Tumour infiltrating lymphocytes - Iovance Biotherapeutics

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Iovance Biotherapeutics; National Cancer Institute (USA)
  • Class Antineoplastics; Cell therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Cell replacements; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma

Most Recent Events

  • 21 Sep 2017 9223144 - updated KDM with the financing info
  • 01 Sep 2017 LN 144 receives Fast Track designation for Malignant melanoma [IV,Infusion] (Late-stage disease) in USA
  • 27 Jun 2017 Lion Biotechnologies is now called Iovance Biotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top